Peringatan Keamanan

Oral LD50 in rat is over 5,000 mg/kg. Side effects include thirst and hunger, unexplained weight loss, increased urination, fatigue, and dry, itchy skin.

Tipranavir

DB00932

small molecule approved investigational

Deskripsi

Tipranavir is a sulfonamide-containing dyhydropyrone and a nonpeptidic protease inhibitor that targets the HIV protease. Tipranavir and ritonavir are coadministered to treat HIV.

Struktur Molekul 2D

Berat 602.664
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) 5-6 hours
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Absorption is limited, although no absolute quantification of absorption is available.

Metabolisme

Hepatic. In vitro metabolism studies with human liver microsomes indicated that CYP 3A4 is the predominant CYP enzyme involved in tipranavir metabolism.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Makanan

1 Data
  • 1. Take with or without food. However, if taken with ritonavir tablets, tipranavir should be taken with food.

Interaksi Obat

1318 Data
Lepirudin The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Lepirudin.
Bivalirudin The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Bivalirudin.
Alteplase The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Alteplase.
Urokinase The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Urokinase.
Reteplase The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Reteplase.
Anistreplase The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Anistreplase.
Tenecteplase The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Tenecteplase.
Drotrecogin alfa The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Drotrecogin alfa.
Streptokinase The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Streptokinase.
Dicoumarol The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Dicoumarol.
Argatroban The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Argatroban.
Ardeparin The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Ardeparin.
Phenindione The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Phenindione.
Fondaparinux The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Fondaparinux.
Warfarin The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Warfarin.
Pentosan polysulfate The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Pentosan polysulfate.
Phenprocoumon The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Phenprocoumon.
Heparin The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Heparin.
Enoxaparin The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Enoxaparin.
Acenocoumarol The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Acenocoumarol.
4-hydroxycoumarin The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with 4-hydroxycoumarin.
Coumarin The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Coumarin.
Ximelagatran The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Ximelagatran.
Desmoteplase The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Desmoteplase.
Ancrod The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Ancrod.
Rivaroxaban The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Rivaroxaban.
Sulodexide The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Sulodexide.
Semuloparin The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Semuloparin.
Idraparinux The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Idraparinux.
Astaxanthin The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Astaxanthin.
Apixaban The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Apixaban.
Otamixaban The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Otamixaban.
Amediplase The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Amediplase.
Danaparoid The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Danaparoid.
Dalteparin The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Dalteparin.
Tinzaparin The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Tinzaparin.
(R)-warfarin The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with (R)-warfarin.
Ethyl biscoumacetate The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Ethyl biscoumacetate.
Nadroparin The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Nadroparin.
Ditazole The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Ditazole.
Sodium citrate The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Sodium citrate.
Dextran The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Dextran.
Bemiparin The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Bemiparin.
Parnaparin The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Parnaparin.
Desirudin The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Desirudin.
Antithrombin Alfa The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Antithrombin Alfa.
Protein C The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Protein C.
Antithrombin III human The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Antithrombin III human.
Letaxaban The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Letaxaban.
Darexaban The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Darexaban.
Nafamostat The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Nafamostat.
Monteplase The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Monteplase.
Gabexate The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Gabexate.
Fluindione The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Fluindione.
Protein S human The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Protein S human.
Brinase The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Brinase.
Clorindione The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Clorindione.
Diphenadione The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Diphenadione.
Tioclomarol The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Tioclomarol.
Melagatran The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Melagatran.
Saruplase The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Saruplase.
(S)-Warfarin The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with (S)-Warfarin.
Tocopherylquinone The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Tocopherylquinone.
Dabigatran The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Dabigatran.
Troxerutin The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Troxerutin.
Edetic acid The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Edetic acid.
Reviparin The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Reviparin.
Dermatan sulfate The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Dermatan sulfate.
SR-123781A The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with SR-123781A.
Abciximab Tipranavir may increase the antiplatelet activities of Abciximab.
Eptifibatide Tipranavir may increase the antiplatelet activities of Eptifibatide.
Ticlopidine Tipranavir may increase the antiplatelet activities of Ticlopidine.
Anagrelide Tipranavir may increase the antiplatelet activities of Anagrelide.
Clopidogrel Tipranavir may increase the antiplatelet activities of Clopidogrel.
Tirofiban Tipranavir may increase the antiplatelet activities of Tirofiban.
Pentoxifylline Tipranavir may increase the antiplatelet activities of Pentoxifylline.
Acetylsalicylic acid Tipranavir may increase the antiplatelet activities of Acetylsalicylic acid.
Dipyridamole Tipranavir may increase the antiplatelet activities of Dipyridamole.
Sulfinpyrazone Tipranavir may increase the antiplatelet activities of Sulfinpyrazone.
Cilostazol Tipranavir may increase the antiplatelet activities of Cilostazol.
Ridogrel Tipranavir may increase the antiplatelet activities of Ridogrel.
Epoprostenol Tipranavir may increase the antiplatelet activities of Epoprostenol.
Resveratrol Tipranavir may increase the antiplatelet activities of Resveratrol.
Nimesulide Tipranavir may increase the antiplatelet activities of Nimesulide.
Tesmilifene Tipranavir may increase the antiplatelet activities of Tesmilifene.
Defibrotide Tipranavir may increase the antiplatelet activities of Defibrotide.
Beraprost Tipranavir may increase the antiplatelet activities of Beraprost.
Ibudilast Tipranavir may increase the antiplatelet activities of Ibudilast.
Andrographolide Tipranavir may increase the antiplatelet activities of Andrographolide.
Caplacizumab Tipranavir may increase the antiplatelet activities of Caplacizumab.
Prasugrel Tipranavir may increase the antiplatelet activities of Prasugrel.
Cangrelor Tipranavir may increase the antiplatelet activities of Cangrelor.
Tranilast Tipranavir may increase the antiplatelet activities of Tranilast.
Triflusal Tipranavir may increase the antiplatelet activities of Triflusal.
Icosapent ethyl Tipranavir may increase the antiplatelet activities of Icosapent ethyl.
Vorapaxar Tipranavir may increase the antiplatelet activities of Vorapaxar.
Trapidil Tipranavir may increase the antiplatelet activities of Trapidil.
Naftopidil Tipranavir may increase the antiplatelet activities of Naftopidil.
Sarpogrelate Tipranavir may increase the antiplatelet activities of Sarpogrelate.
Ifetroban Tipranavir may increase the antiplatelet activities of Ifetroban.

Target Protein

Gag-Pol polyprotein gag-pol
Pol polyprotein pol

Referensi & Sumber

Synthesis reference: Franz Klingler, "Enantioselective hydrogenation of intermediates in the synthesis of tipranavir." U.S. Patent US20040224990, issued November 11, 2004.
Artikel (PubMed)
  • PMID: 16122817
    Doyon L, Tremblay S, Bourgon L, Wardrop E, Cordingley MG: Selection and characterization of HIV-1 showing reduced susceptibility to the non-peptidic protease inhibitor tipranavir. Antiviral Res. 2005 Oct;68(1):27-35.
  • PMID: 16620137
    Authors unspecified: Tipranavir: PNU 140690, tipranivir. Drugs R D. 2006;7(1):55-62.
  • PMID: 17712762
    Temesgen Z, Feinberg J: Tipranavir: a new option for the treatment of drug-resistant HIV infection. Clin Infect Dis. 2007 Sep 15;45(6):761-9. Epub 2007 Aug 7.
  • PMID: 18158073
    Luna B, Townsend MU: Tipranavir: the first nonpeptidic protease inhibitor for the treatment of protease resistance. Clin Ther. 2007 Nov;29(11):2309-18.

Contoh Produk & Brand

Produk: 4 • International brands: 0
Produk
  • Aptivus
    Capsule, liquid filled • 250 mg/1 • Oral • US • Approved
  • Aptivus
    Solution • 100 mg/1mL • Oral • US • Approved
  • Aptivus
    Capsule • 250 mg • Oral • Canada • Approved
  • Aptivus
    Capsule • 250 mg • Oral • EU • Approved

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul